Eli Lilly shares climb over 4% as obesity drug data fuels Q2 revenue surge
Eli Lilly & Co. (LLY) stock rose about 4% on October 7, 2026 after trial data for its obesity drugs Zepbound and Foundayo impressed investors. The company reported Q2 2026 revenue of $23.0 billion, up 48% year‑over‑year, driven by Mounjaro ($9.9 billion) and Zepbound ($4.9 billion). Full‑year 2026 guidance was lifted to $85‑$87 billion. Analysts raised price targets, with some citing $1,500 as a new objective.
Why it matters
The price increase reflects market confidence that Lilly’s obesity franchise will sustain high growth, supporting the premium valuation of the stock (the company’s own guidance and analyst price targets indicate this). Investors may see continued upside if upcoming data and product launches meet expectations.
Key facts
- 1Q2 2026 revenue was $23.0 billion, up 48% year over year. timothysykes.com
- 2Mounjaro generated $9.9 billion in Q2 2026. timothysykes.com
- 3Zepbound generated $4.9 billion in Q2 2026. timothysykes.com
- 4Full‑year 2026 revenue guidance was raised to $85–$87 billion. timothysykes.com
- 5Eli Lilly stock rose 4.14% on the day. timothysykes.com
- 6Eli Lilly stock rose 4.07% on the day. stockstotrade.com
Open questions
- Two sources report slightly different intraday price gains (4.14% vs 4.07%).
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.